MASCC Guidelines
Evidence-based clinical practice guidelines created by the MASCC study groups.
To access the full guidelines and guideline summary documents, simply log into your member account (for MASCC members) or provide your email address below (for non-members).
Antiemetics Study Group
MASCC/ESMO Antiemetic Guidelines (2023 Update)
Introduction to the 2023 guidelines update.
Herrstedt J et al. Supportive Care in Cancer (2023).
I Emetic classification of antineoplastic agents
Jordan K et al. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation. Supportive Care in Cancer (2023).
II Highly emetic chemotherapy
Herrstedt J et al. 2023 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Supportive Care in Cancer (2023).
III Moderately emetic chemotherapy
Scotté F et al. 2023 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Supportive Care in Cancer (2023).
IV Low or minimally emetic chemotherapy
Olver I et al. 2023 updated MASCC/ESMO consensus recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Supportive Care in Cancer (2023).
V Multiple-day, high-dose chemotherapy, refractory, break-through nausea and vomiting
Rapoport BL et al. 2023 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Supportive Care in Cancer (2023).
VI CAMs and non-pharmacological interventions
Molassiotis A et al. 2023 MASCC/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies. Supportive Care in Cancer (2023).
VII Radiotherapy-induced nausea and vomiting
Ruhlmann CH et al. 2023 updated MASCC/ESMO consensus recommendations: Prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting. Supportive Care in Cancer (2023).
VIII Guidelines for patients
Affronti ML et al. MASCC 2023 Patient-Centered Antiemetic Guidelines and Education Statements: an evidence-based and consensus resource for patients. Supportive Care in Cancer (2024).
(2023)
(2023)
(2023)
(2023)
Antiemetics in advanced cancer (MASCC updated guideline)
Davis M et al. Supportive Care in Cancer (2021).
(2021)
(2021)
Nausea and vomiting in malignant bowel obstruction
Davis M et al. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. Supportive Care in Cancer (2021).
(2021)
(2021)
Bone and Musculoskeletal Study Group
Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline
Yarom N et al. Journal of Clinical Oncology (2019).
(2019)
(2019)
Cancer Pain Subgroup
Cannabis for cancer-related pain and risk of harms and adverse events
To J et al. Supportive Care in Cancer (2023).
(2023)
(2023)
De Feo G et al. Supportive Care in Cancer (2023).
(2023)
(2023)
Alderman B et al. Supportive Care in Cancer (2022).
(2022)
(2022)
Immuno-Oncology Subgroup
Rapoport BL et al. Supportive Care in Cancer (2020).
Cancer immunotherapy–related adverse events: causes and challenges
Blidner AG et al. Supportive Care in Cancer (2020).
Cooksley T et al. Supportive Care in Cancer (2020).
Suarez-Almazor ME et al. Supportive Care in Cancer (2020).
Shannon VR et al. Supportive Care in Cancer (2020).
Choi J et al. Supportive Care in Cancer (2020).
Dougan M et al. Supportive Care in Cancer (2020).
Mucositis Study Group
Mucositis Study Group, MASCC/ISOO mucositis guidelines – Summary – Original article
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Elad S et al. Cancer (2020).
(2019 - 2020 version)
(2019 - 2020 version)
Guideline Summary Translations – Available in Arabic, French, German, Greek, Japanese, Portuguese (Brazil and Portugal dialects) and Spanish.
Mucositis Study Group, MASCC/ISOO mucositis guidelines – Introduction to part 1
The MASCC/ISOO Mucositis Guidelines 2019 Update: introduction to the first set of articles
Elad S. Supportive Care in Cancer (2019).
Mucositis Study Group, MASCC/ISOO mucositis guidelines – Introduction to part 2
The MASCC/ISOO Mucositis Guidelines 2019: the second set of articles and future directions
Elad S. Supportive Care in Cancer (2020).
Mucositis Study Group, MASCC/ISOO mucositis guidelines – Methods
Development of the MASCC/ISOO clinical practice guidelines for mucositis: an overview of the methods
Ranna V et al. Supportive Care in Cancer (2019).
Mucositis Study Group, MASCC/ISOO mucositis guidelines – Basic oral care
Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines
Hong CHL et al. Supportive Care in Cancer (2019).
(2019 - 2020 version)
(2019 - 2020 version)
Mucositis Study Group, MASCC/ISOO mucositis guidelines – Photobiomodulation therapy / laser
Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines
Zadik Y et al. Supportive Care in Cancer (2019).
(2019 - 2020 version)
(2019 - 2020 version)
Mucositis Study Group, MASCC/ISOO mucositis guidelines – Anti-inflammatory agents
Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines
Ariyawardana A et al. Supportive Care in Cancer (2019).
(2019 - 2020 version)
(2019 - 2020 version)
Mucositis Study Group, MASCC/ISOO mucositis guidelines – Natural and miscellaneous agents – Part 1
Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements
Yarom N et al. Supportive Care in Cancer (2019).
(2019 - 2020 version)
(2019 - 2020 version)
Mucositis Study Group, MASCC/ISOO mucositis guidelines – Natural and miscellaneous agents – Part 2
Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines – part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents
Yarom N et al. Supportive Care in Cancer (2020).
(2019 - 2020 version)
(2019 - 2020 version)
Mucositis Study Group, MASCC/ISOO mucositis guidelines – Antimicrobials, mucosal coating agents, anesthetics, and analgesics
Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines
Saunders DP et al. Supportive Care in Cancer (2020).
(2019 - 2020 version)
(2019 - 2020 version)
Mucositis Study Group, MASCC/ISOO mucositis guidelines – Cryotherapy
Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines
Correa MEP et al. Supportive Care in Cancer (2019).
(2019 - 2020 version)
(2019 - 2020 version)
Mucositis Study Group, MASCC/ISOO mucositis guidelines – Growth factors and cytokines
Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines
Logan RM et al. Supportive Care in Cancer (2020).
(2019 - 2020 version)
(2019 - 2020 version)
Mucositis Study Group, MASCC/ISOO mucositis guidelines – all interventions for GI mucositis
Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines
Bowen JM et al. Supportive Care in Cancer (2019).
(2019 - 2020 version)
(2019 - 2020 version)
Mucositis Study Group, MASCC/ISOO mucositis guidelines – sub-analysis: all interventions in pediatric patients
MASCC/ISOO clinical practice guidelines for the management of mucositis: sub-analysis of current interventions for the management of oral mucositis in pediatric cancer patients
Miranda-Silva W et al. Supportive Care in Cancer (2020).
(2019 - 2020 version)
(2019 - 2020 version)
Mucositis Study Group, MASCC/ISOO mucositis guidelines – systematic review – pathogenesis
The pathogenesis of mucositis: updated perspectives and emerging targets
Bowen J et al. Supportive Care in Cancer (2019).
(2019 - 2020 version)
(2019 - 2020 version)
Mucositis Study Group, MASCC/ISOO mucositis guidelines – systematic review – risk prediction
Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action
Wardill HR et al. Supportive Care in Cancer (2020).
(2019 - 2020 version)
(2019 - 2020 version)
Oncodermatology Study Group
Behroozian T et al. eClinicalMedicine (2023).
Behroozian T et al. Lancet Oncology (2023).
(2023)
(2023)
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities – UNDER REVISION
Lacouture ME et al. Supportive Care in Cancer (2011)
(2011)
Oral Care Study Group
Raber-Durlacher JE et al. Supportive Care in Cancer (2024).
Zadik Y et al. Supportive Care in Cancer (2024).
Yarom N et al. Supportive Care in Cancer (2024).
Hong C et al. Supportive Care in Cancer (2024).
MASCC/ISOO Clinical Practice Statement: Management of oral complications of targeted therapy
Villa A et al. Supportive Care in Cancer (2024).
Raber-Durlacher JE et al. Supportive Care in Cancer (2024).
Hong C et al. Supportive Care in Cancer (2024).
Peterson DE et al. Journal of Clinical Oncology (2024).
(2024)
(2024)
(2024)
Management of oral problems in patients with advanced cancer (MASCC/ISOO expert opinion)
Jones JA et al. Supportive Care in Cancer (2022).
(2022)
(2022)
Salivary gland hypofunction and/or xerostomia induced by nonsurgical cancer therapies (ISOO/MASCC/ASCO Guideline)
Mercadante V et al. Supportive Care in Cancer (2021).
(2021)
(2021)
Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline
Yarom N et al. Journal of Clinical Oncology (2019).
(2019)
(2019)
Palliative Care Study Group
Hayes J et al. Supportive Care in Cancer (2024).
(2024)
(2024)
Management of oral problems in patients with advanced cancer (MASCC/ISOO expert opinion)
Jones JA et al. Supportive Care in Cancer (2022).
(2022)
(2022)
Management of malignant bowel obstruction in advanced cancer (MASCC multidisciplinary evidence-based recommendations)
Madariaga A et al. Supportive Care in Cancer (2022).
Antiemetics in advanced cancer (MASCC updated guideline)
Davis M et al. Supportive Care in Cancer (2021).
(2021)
(2021)
Nausea and vomiting in malignant bowel obstruction
Davis M et al. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. Supportive Care in Cancer (2021).
(2021)
(2021)
The use of clinically assisted nutrition in patients with advanced cancer (MASCC expert opinion/guidance)
Alderman B et al. Supportive Care in Cancer (2021).
(2021)
(2021)
Survivorship Study Group
Hart NH et al. Supportive Care in Cancer (2024).
(2024)
(2024)
(2024)
(2024)
Guideline Summary Translations – Available in Arabic, Chinese, Croatian, Dutch, French, German, Greek, Hebrew, Italian, Japanese, Polish, Portuguese, and Spanish.
Endorsed Guidance
Exercise recommendation for people with bone metastases: Expert consensus for health care providers and exercise professionals
Campbell KL et al. JCO Oncology Practice (2022).
Endorsement: Hart NH et al. Supportive Care in Cancer (2022)
Cancer-Related Fatigue Self-Management Support Practice Framework
Supporting publications:
Agbejule OA et al. Journal of Cancer Survivorship (2023).
Self-management support for cancer-related fatigue: A systematic review
Agbejule OA et al. International Journal of Nursing Studies (2022).
Agbejule OA et al. BMC Cancer (2021).
Agbejule OA et al. Supportive Care in Cancer (2023).
Patel P et al. European Journal of Cancer (2021).
Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline
Patel P et al. Pediatric Blood Cancer (2022).
Treatment of breakthrough and prevention of refractory chemotherapy-induced nausea and vomiting in pediatric cancer patients: Clinical practice guideline update
Patel P et al. Pediatric Blood Cancer (2023).
Lehrnbecher T et al. Journal of Clinical Oncology (2023).
Patel P et al. eClinicalMedicine (2023).
Patel P et al. European Journal of Cancer (2021).